{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:01:22Z","timestamp":1777320082324,"version":"3.51.4"},"reference-count":115,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Peripheral T\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>), not otherwise specified (<jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>) and angioimmunoblastic T\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">AITL<\/jats:styled-content>) are the most frequent of more than 20 mature <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content> entities featuring a broad spectrum of morphological, immunophenotypic, molecular and clinical characteristics. Unfortunately, recent progress in understanding the (epi)genetic background of <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content> has not been met with similar advances in treatment. Thus, <jats:styled-content style=\"fixed-case\">CHO<\/jats:styled-content>(E)P [cyclophosphamide, doxorubicin, vincristine, and prednisone (plus etoposide)] remains standard first\u2010line therapy. Patients without comorbidities achieving complete or partial remission proceed to autologous stem cell transplantation. With this approach about 50% of patients survive long\u2010term. Patients relapsing after or progressing during first\u2010line therapy have a dismal prognosis. They receive salvage gemcitabine\u2010therapy followed by allogeneic transplantation whenever possible. After allografting, approximately half of the patients survive long\u2010term; any other treatment is palliative. New drugs investigated in phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> studies achieved response rates between 10% and 30%; long\u2010term remissions are the exception to the rule. While most new drugs are not licensed and not readily available, a plethora of other innovative drugs targeting (epi\u2010)genetic abnormalities are in early development. These, together with combinations of new and old drugs, will hopefully increase response to first\u2010line therapy, bridge more patients to transplantation, and finally improve prognosis for all patients with <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.14473","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T15:49:57Z","timestamp":1481989797000},"page":"851-866","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["How I manage peripheral T\u2010cell lymphoma, not otherwise specified and angioimmunoblastic T\u2010cell lymphoma: current practice and a glimpse into the future"],"prefix":"10.1111","volume":"176","author":[{"given":"Norbert","family":"Schmitz","sequence":"first","affiliation":[{"name":"Department of Haematology, Oncology and Stem Cell Transplantation Asklepios Hospital St. Georg Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"de Leval","sequence":"additional","affiliation":[{"name":"Institute of Pathology University Hospital Lausanne and University of Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5540"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13855"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv201"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2296"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10737"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182991415"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6327"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707141"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-584953"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391748"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.050"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.79"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw011"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1111708"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3719"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.240"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017632"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00023-X"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.004"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20999"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.2456"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3647"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.320"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt378"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.11.004"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-004-1077-2"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.8040"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70161-5"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147074"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq359"},{"key":"e_1_2_10_39_1","unstructured":"Hopfinger G. Krasniqi F. Reimer P. Schmitz N.&Wulf G.(2016)Periphere T\u2010Zell Lymphome. In: Onkopedia https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/periphere-t-zell-lymphome\/@@view\/html\/index.html."},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V124.21.803.803","article-title":"Duvelisib (IPI\u2010145), a phosphoinositide\u20103\u2010kinase\u2010\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T\u2010cell lymphoma","volume":"124","author":"Horwitz S.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181971591"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536359"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq698"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-671834"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0136-y"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V124.21.396.396","article-title":"The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT\u2010330) demonstrates broad and durable clinical activity in relapsed\/refractory Non Hodgkin's Lymphoma (NHL)","volume":"124","author":"Kuruvilla J.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70265-7"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.12.6219"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4628"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1366"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.133074"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408542"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555763"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpdhp.2015.09.005"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200103000-00015"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-055145"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2009.01.002"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08003.x"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.126300"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3883"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27733"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555946"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.113696"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn022"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318268d9ff"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-516245"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759"},{"key":"e_1_2_10_71_1","first-page":"358","article-title":"Allogeneic stem cell transplantation results in a low relapse rate in patients with peripheral T\u2010cell lymphoma","volume":"112","author":"Nickelsen M.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_72_1","first-page":"287","article-title":"Patients with mature T\u2010cell lymphoma show high relapse rates after high dose therapy and autologous stem cell transplantation","volume":"112","author":"Nickelsen M.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182785610"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531509"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000571"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2873"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2468-y"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20092042"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0463"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13202"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26833"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.06.003"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.069757"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.17.3766"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.357"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084913"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2872"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.261"},{"key":"e_1_2_10_94_1","first-page":"1272","article-title":"Long\u2010term disease\u2010free survival in patients with angioimmunoblastic T\u2010cell lymphoma after high\u2010dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig J.","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_10_96_1","first-page":"8507","article-title":"Allogeneic or autologous transplantation as first\u2010line therapy for younger patients with peripheral T\u2010cell lymphoma: results of the interim analysis of the AATT trial","volume":"33","author":"Schmitz N.","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"e_1_2_10_99_1","first-page":"735","article-title":"Peripheral T\u2010cell lymphoma with t(6;14)(p25;q11.2) translocation presenting with massive splenomegaly","volume":"464","author":"Somja J.","year":"2014","journal-title":"Virchows Archiv"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05478.x"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404045"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103"},{"key":"e_1_2_10_105_1","doi-asserted-by":"crossref","first-page":"S7500","DOI":"10.1200\/JCO.2016.34.15_suppl.7500","article-title":"Alemtuzumab added to CHOP for treatment of peripheral T\u2010cell lymphoma (pTNHL) of the elderly: final results of 116 patients treated in the international ACT\u20102 phase III trial","volume":"34","author":"Truemper L.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-698977"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_10_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544809"},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-310342"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6327"},{"key":"e_1_2_10_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.63"},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200012000-00006"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2916"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139253"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp508"},{"key":"e_1_2_10_116_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146977"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14473","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T20:45:01Z","timestamp":1696279501000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,16]]},"references-count":115,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/bjh.14473"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14473","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,16]]},"assertion":[{"value":"2016-12-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}